Who is sponsoring NCT04008849?

NCT04008849 is sponsored by Magenta Therapeutics, Inc..

What drugs are being tested in NCT04008849?

Interventions in NCT04008849: Safety and efficacy assessments.

What condition does NCT04008849 study?

NCT04008849 studies Inherited Metabolic Disorders (IMD).

Is NCT04008849 still recruiting?

NCT04008849 is currently terminated. Last updated 15 March 2021.

Last reviewed 2021-03-15 · How we verify

NCT04008849: IMD-002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

Terminated Last updated 15 March 2021

What this trial tests

trial testing Safety and efficacy assessments in Inherited Metabolic Disorders (IMD) in 3 participants. Terminated before completion.

Timeline

21 May 2019

Primary endpoint
8 October 2020

8 October 2020

Quick facts

Lead sponsor	Magenta Therapeutics, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	21 May 2019
Primary completion	8 October 2020
Estimated completion	8 October 2020
Sites	1 location across United States

Drugs / interventions tested

Safety and efficacy assessments — full drug profile →

Conditions studied

Inherited Metabolic Disorders (IMD) — all drugs for Inherited Metabolic Disorders (IMD) →

Sponsor

Magenta Therapeutics, Inc. — full company profile →

Who can join

Under 16, any sex, with Inherited Metabolic Disorders (IMD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Safety and efficacy assessments

Trials testing the same drug.

NCT04836377 — A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02 · terminated
NCT04437771 — Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy · active not recruiting
NCT02786511 — Longterm Follow-up of Subjects Treated With bb2121 · completed

Other recruiting trials for Inherited Metabolic Disorders (IMD)

Currently open trials in the same condition.

NCT04528355 — Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC · recruiting

Other Magenta Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05223699 — Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) · Phase 1 · terminated
NCT03406962 — MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04008849 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Magenta Therapeutics, Inc.
Last refreshed: 15 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04008849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing